Postpartum navigation missed its primary goal but raised postpartum visits and primary care use among Medicaid-insured ...
When Erica Plybeah launched MedHaul in 2017, she didn’t just think medical transportation was a barrier to care. She’d lived ...
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen. After a median follow-up of 23 months, median PFS ...
Eliot F. Battle, MD, cofounder and CEO of Cultura Dermatology & Laser Center in Washington, DC, and cochair of Skin of Color ...
Despite expanding treatment options for rare glomerular diseases such as immunoglobulin A nephropathy (IgAN) and focal ...
Adults and adolescents with alopecia areata had nearly 8 times higher odds of near-complete scalp hair regrowth on an oral ...
Under this rule, CMS opted for the term SRP as opposed to gender-affirming care because the latter "inaccurately describes ...
Dr. Haumschild identifies several contributors to SGLT2 inhibitor underuse, starting with fragmentation in care. He says the biggest issue is often the gap between identifying an ...
SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.
The Ambulatory Specialty Model (ASM) has the potential to reduce chronic disease costs by holding specialists accountable for ...
D’Amico concluded that remigromig is the first biologic with a novel mechanism of action that demonstrated a noninferior ...
Medicare beneficiaries using lower-priced negotiated drugs experienced out-of-pocket savings under the Medicare Drug Price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results